Rhumbline Advisers Has $18.57 Million Holdings in BIO-TECHNE Corp (TECH)

Share on StockTwits

Rhumbline Advisers boosted its holdings in shares of BIO-TECHNE Corp (NASDAQ:TECH) by 26.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 128,331 shares of the biotechnology company’s stock after purchasing an additional 27,014 shares during the period. Rhumbline Advisers owned about 0.34% of BIO-TECHNE worth $18,572,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Advisors Asset Management Inc. increased its holdings in shares of BIO-TECHNE by 2.0% in the fourth quarter. Advisors Asset Management Inc. now owns 11,467 shares of the biotechnology company’s stock valued at $1,660,000 after purchasing an additional 220 shares in the last quarter. Xact Kapitalforvaltning AB grew its holdings in BIO-TECHNE by 9.0% during the 4th quarter. Xact Kapitalforvaltning AB now owns 6,037 shares of the biotechnology company’s stock worth $874,000 after acquiring an additional 500 shares during the period. Oppenheimer Asset Management Inc. grew its holdings in BIO-TECHNE by 3.3% during the 4th quarter. Oppenheimer Asset Management Inc. now owns 18,274 shares of the biotechnology company’s stock worth $2,644,000 after acquiring an additional 592 shares during the period. Pendal Group Ltd grew its holdings in BIO-TECHNE by 18.3% during the 4th quarter. Pendal Group Ltd now owns 4,641 shares of the biotechnology company’s stock worth $672,000 after acquiring an additional 717 shares during the period. Finally, Bradley Foster & Sargent Inc. CT acquired a new stake in BIO-TECHNE during the 4th quarter worth $747,000. Hedge funds and other institutional investors own 99.00% of the company’s stock.

A number of analysts have commented on the stock. Craig Hallum reaffirmed a “hold” rating and set a $179.00 target price (up previously from $154.00) on shares of BIO-TECHNE in a report on Tuesday, February 5th. ValuEngine raised shares of BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 5th. Goldman Sachs Group assumed coverage on shares of BIO-TECHNE in a report on Wednesday, October 17th. They set a “neutral” rating and a $190.00 target price for the company. BidaskClub lowered shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a report on Thursday, October 18th. Finally, Zacks Investment Research lowered shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $188.13.

Shares of NASDAQ TECH opened at $183.73 on Monday. The firm has a market cap of $6.94 billion, a PE ratio of 45.14, a PEG ratio of 4.15 and a beta of 1.18. BIO-TECHNE Corp has a twelve month low of $129.72 and a twelve month high of $206.04. The company has a current ratio of 4.35, a quick ratio of 3.31 and a debt-to-equity ratio of 0.49.

BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings results on Tuesday, February 5th. The biotechnology company reported $1.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.08. The company had revenue of $174.50 million for the quarter, compared to analysts’ expectations of $171.39 million. BIO-TECHNE had a net margin of 14.02% and a return on equity of 13.90%. The business’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same period last year, the firm posted $1.02 earnings per share. As a group, equities analysts anticipate that BIO-TECHNE Corp will post 3.68 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 15th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.70%. BIO-TECHNE’s dividend payout ratio is 31.45%.

TRADEMARK VIOLATION NOTICE: “Rhumbline Advisers Has $18.57 Million Holdings in BIO-TECHNE Corp (TECH)” was originally posted by Zolmax and is the sole property of of Zolmax. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://zolmax.com/investing/rhumbline-advisers-has-18-57-million-holdings-in-bio-techne-corp-tech/2891569.html.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Story: Cost of Capital Explained

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Packaging Corp Of America  Expected to Announce Earnings of $1.97 Per Share
Packaging Corp Of America Expected to Announce Earnings of $1.97 Per Share
Raymond James Reiterates “C$20.00” Price Target for Hydro One
Raymond James Reiterates “C$20.00” Price Target for Hydro One
Finning International  PT Lowered to C$29.00
Finning International PT Lowered to C$29.00
Raymond James Analysts Give Coeur Mining  a $6.50 Price Target
Raymond James Analysts Give Coeur Mining a $6.50 Price Target
Boyd Gaming  Issues Quarterly  Earnings Results
Boyd Gaming Issues Quarterly Earnings Results
Delphi Technologies  Posts  Earnings Results, Beats Estimates By $0.19 EPS
Delphi Technologies Posts Earnings Results, Beats Estimates By $0.19 EPS


Leave a Reply

 
© 2006-2019 Zolmax.